Publications and events
By: Who Press
.
Publisher: Switzerland World Health Organization 2018Edition: Vol. 32(2).Description: 219-228.Subject(s): DRUG STORE MANAGEMENTOnline resources: Click here
In:
Who drug informationSummary: Geneva – In its annual review of its R&D
Blueprint, WHO has added “Disease X” to
the research priorities for pathogens that
could cause serious epidemics and for which
there are no or insufficient countermeasures.
Disease X represents a known or unknown
pathogen that is yet to be found to have
potential to cause a serious international
epidemic.
The list was first published in December
2015 and is reviewed annually. It now
includes (in no particular order) CrimeanCongo haemorrhagic fever (CCHF), Ebola
virus disease and Marburg virus disease,
Lassa fever, Middle East respiratory
syndrome coronavirus (MERS-CoV) and
Severe Acute Respiratory Syndrome (SARS),
Nipah and henipaviral diseases, Rift Valley
fever (RVF), Zika, and Disease X. The R&D
Blueprint explicitly seeks to enable crosscutting preparedness that is also relevant for
a future Disease X.
| Item type | Current location | Call number | Status | Date due | Barcode | Item holds |
|---|---|---|---|---|---|---|
Articles Abstract Database
|
School of Pharmacy Archieval Section | Not for loan | 2018270 |
Geneva – In its annual review of its R&D
Blueprint, WHO has added “Disease X” to
the research priorities for pathogens that
could cause serious epidemics and for which
there are no or insufficient countermeasures.
Disease X represents a known or unknown
pathogen that is yet to be found to have
potential to cause a serious international
epidemic.
The list was first published in December
2015 and is reviewed annually. It now
includes (in no particular order) CrimeanCongo haemorrhagic fever (CCHF), Ebola
virus disease and Marburg virus disease,
Lassa fever, Middle East respiratory
syndrome coronavirus (MERS-CoV) and
Severe Acute Respiratory Syndrome (SARS),
Nipah and henipaviral diseases, Rift Valley
fever (RVF), Zika, and Disease X. The R&D
Blueprint explicitly seeks to enable crosscutting preparedness that is also relevant for
a future Disease X.
There are no comments for this item.